Targeted anti-estrogens to treat and prevent diseases in women

Molecular Medicine Today

Volumn 2, Issue 5, 1996, Pages 218-223

  Tonetti, Debra A ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN;

ANIMAL; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CORONARY ARTERY DISEASE; ENDOMETRIUM TUMOR; ESTROGEN THERAPY; FEMALE; HUMAN; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW;

ANIMALS; BASE SEQUENCE; BREAST NEOPLASMS; CORONARY DISEASE; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MOLECULAR SEQUENCE DATA; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTORS, ESTROGEN; TAMOXIFEN;

EID: 0030139852     PISSN: 13574310     EISSN: None     Source Type: Journal    
DOI: 10.1016/1357-4310(96)88775-2     Document Type: Review

References (35)

1. Klein-Hitpaß, L., Schorpp, M., Wagner, U. and Ryffel, G.U. (1986) An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells, Cell 46, 1053-1061
2. Beatson, G.T. (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases, Lancet ii, 104-107; 162-167
3. Boyd, S. (1900) On oophorectomy in cancer of the breast, Br. Med. J. 2, 1161-1167
4. Jensen, E.V. and Jacobson, H.I. (1962) Basic guides to the mechanism of estrogen action, Recent Prog. Horm. Res. 18, 387-414
5. Gorski, J. et al. (1968) Hormone receptors: studies on the interaction of estrogen with the uterus, Recent Prog. Horm. Res. 24, 45-80
6. Jensen, E.V. et al. (1971) Estrogen receptors and breast cancer response to adrenalectomy, Natl Cancer Inst. Monogr. 34, 55-70
7. McGuire, W.L., Carbone, P.P. and Vollmer, E.P. (eds) (1975) Estrogen Receptors in Human Breast Cancer, Raven Press
8. Jordan, V.C. et al. (1988) Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast, CRC Crit. Rev. Clin. Lab. Sci. 26, 97-152
9. Jaiyesimi, I.A., Buzdar, A.U., Decker, D.A. and Hortobagyi, G.N. (1995) Use of tamoxifen for breast cancer: twenty-eight years later, J. Clin. Oncol. 13, 513-529
10. Jordan, V.C. (1994) The development of tamoxifen for breast cancer therapy, in Long-term Tamoxifen Treatment for Breast Cancer (Jordan, V.C., ed.), pp. 3-26, The University of Wisconsin Press
11. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy, Lancet 339, 1-15; 71-85
12. Jordan, V.C. (1994) Molecular mechanisms of antiestrogen action in breast cancer, Breast Cancer Res. Treat. 31, 41-52
13. Tonetti, D.A. and Jordan, V.C. (1995) Possible mechanisms in the emergence of tamoxifen-resistant breast cancer, Anti-cancer Drugs 6, 498-507
14. Love, R.R. et al. (1992) Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. New Engl. J. Med. 326, 852-856
15. Kristensen, B. et al. (1994) Tamoxifen and bone metabolism in postmenopausal low risk breast cancer patients: a randomized study, J. Clin. Oncol. 12, 992-997
16. Love, R.R. et al. (1991) Effects of tamoxifen on cardiovascular risk factors in postmenopausal women, Ann. Intern. Med. 115, 860-864
17. McDonald, C.C. and Stewart, H.J. for the Scottish Breast Cancer Committee (1991) Fatal myocardial infarctions in the Scottish adjuvant tamoxifen trial, Br. Med. J. 303, 435-437
18. Gylling, H., Mäntylä, E. and Miettinen, T.A. (1992) Tamoxifen decreases serum cholesterol by inhibiting cholesterol synthesis, Atherosclerosis 96, 245-247
19. Wiseman, H., Paganga, G., Rice-Evans, C. and Halliwell, B. (1993) Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen? Biochem. J. 292, 635-638
20. Gottardis, M.M., Robinson, S.P., Satyaswaroop, P.G. and Jordan, V.C. (1988) Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse, Cancer Res. 48, 812-815
21. Fornander, T. et al. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet i, 117-120
22. Fisher, B. et al. (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National surgical adjuvant breast and bowel project (NSABP) B-14, J. Natl Cancer Inst. 80, 527-537
23. Jordan, V.C. and Assikis, V.J. (1995) Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin. Cancer Res. 1, 467-472
24. Berry, M., Metzger, D. and Chambon, P. (1990) Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J. 9, 2811-2818
25. Dana, S.L. et al. (1994) Novel estrogen response elements identified by genetic selection in yeast are differentially responsive to estrogens and antiestrogens in mammalian cells, Mol. Endocrinol. 8, 1193-1207
26. Catherino, W.H. and Jordan, V.C. (1995) Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue, Cancer Lett. 92, 39-47
27. Tzukerman, M.T. et al. (1994) Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions, Mol. Endocrinol. 8, 21-30
28. Fritsch, M. and Wolf, D.M. (1994) Symptomatic side effects of tamoxifen therapy, in Long-term Tamoxifen Treatment for Breast Cancer (Jordan, V.C., ed.), pp. 235-255, The University of Wisconsin Press
29. Lerner, L.J. and Jordan, V.C. (1990) Development of antiestrogens and their use in breast cancer: Eighth Cain Memorial Award Lecture, Cancer Res. 50, 4177-1189
30. Jordan, V.C. (1995) Alternate antiestrogens and approaches to the prevention of breast cancer, J. Cell. Biochem. 22 (Suppl.), 51-57
31. Hasmann, M., Rattel, B. and Löser, R. (1994) Preclinical data for droloxifene, Cancer Lett. 84, 101-116
32. Rauschning, W. and Pritchard, K.I. (1994) Droloxifene, a new antiestrogen: its role in metastatic breast cancer, Breast Cancer Res. Treat. 31, 83-94
33. Jordan, V.C., Phelps, E. and Lindgren, J.U. (1987) Effects of antiestrogens on bone in castrated and intact female rats. Breast Cancer Res. Treat. 10, 31-35
34. Black, L.J. et al. (1994) Raloxifene (LY139481HC1) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats, J. Clin. Invest. 93, 63-69
35. Gottardis, M.M. and Jordan, V.C. (1987) Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model, Cancer Res. 46, 4020-4024